Saturday 17 October 2026
Export BRTX’s income statement to Excel — free account
Biorestorative Therapies, Inc.
BRTX Healthcare Biotechnology
Biorestorative Therapies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $359,700.00, down 10.3% from fiscal 2024. In the quarter to March 2026, revenue fell 7.20%, EPS grew 81.3% and free cash flow fell 35.3%, each against the same quarter a year earlier.
1.54
0.08
+5.48%
Follow BRTX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 3 | 4 | 4 | 4 | 3 | 2 | 3 | 6 | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.48 | 1.38 | 2.49 | 4.11 | 5.60 | 7.06 | 0.05 | 3.24 | 18.27 | 37.36 |
Altman Z-Score |
(70.97) | (20.01) | (19.34) | (15.24) | (10.92) | (30.36) | (105.08) | (105.23) | (61.83) | (57.68) |
Altman Z″-Score (non-manufacturers) |
(162.40) | (41.31) | (37.43) | (4.59) | 5.29 | (68.64) | (275.34) | (268.71) | (157.35) | (144.45) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(0.22) | (0.24) | (0.23) | (0.30) | (0.23) | (0.95) | 0.00 | (0.23) | (1.09) | (1.28) |
Beneish M-Score |
(7.56) | 1.13 | (5.87) | (3.87) | (15.47) | (12.87) | (26.98) | (31.71) | (14.66) | (16.79) |
P/B ratio |
1.55 | 0.07 | 0.04 | 0.03 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.07 | 0.04 | 0.03 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
(6.20) | (24.90) | (72.10) | (117.42) | (447.35) | 22.72 | 1.24 | 6.90 | 15.09 | 44.67 |
EV/EBITDA |
0.14 | 0.88 | 0.70 | 0.75 | 0.82 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
0.21 | 1.21 | 1.63 | 2.38 | 6.18 | (0.89) | (0.02) | (0.15) | (0.32) | (0.32) |
EV/FCF |
0.18 | 1.04 | 1.35 | 1.91 | 6.06 | (0.87) | (0.02) | (0.15) | (0.31) | (0.31) |
Quick Ratio |
0.80 | 2.91 | 4.25 | 33.53 | 57.81 | 2.95 | 0.00 | 0.02 | 0.06 | 0.01 |
Current Ratio |
0.84 | 2.97 | 4.37 | 34.36 | 59.01 | 3.05 | 0.01 | 0.02 | 0.06 | 0.01 |
Net Debt/EBITDA |
0.19 | 0.94 | 0.74 | 0.78 | 0.83 | (0.89) | (0.11) | (0.08) | 0.03 | (0.04) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.85% | 98.23% | 35.59% | 43.94% | 11.05% | 18.85% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.01 | (3.21) | (0.04) | (0.06) | (0.03) | (0.06) |
Asset Turnover |
0.04 | 0.03 | 0.01 | 0.01 | 0.00 | 0.03 | 0.10 | 0.08 | 0.05 | 0.02 |
Operating CF/Net income |
0.76 | 0.92 | 0.62 | 0.32 | 0.08 | 0.17 | 0.47 | 0.41 | 0.41 | 0.58 |
Capex/Depreciation |
(0.55) | (0.56) | (1.03) | (3.65) | (0.03) | 0.00 | (0.01) | (0.01) | 0.00 | (0.24) |
Interest Coverage |
58.78 | 18.76 | 27.56 | 1,621.71 | (14.49) | (1.68) | (5.74) | (8.20) | (17.89) | (35.13) |
| (321.48%) | (97.03%) | (80.73%) | (98.91%) | (437.56%) | 159.81% | 136.79% | 161.75% | 159.58% | 193.88% | |
| (174.11%) | (72.15%) | (71.73%) | (95.12%) | (330.62%) | (387.82%) | (1,101.88%) | (848.38%) | (565.79%) | (480.19%) | |
ROIC |
0.00% | 0.00% | 0.00% | (1,095.29%) | (2,159.78%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
6,268.49% | (115.73%) | (113.99%) | (123.72%) | (209.55%) | (520.90%) | 107.84% | 140.67% | 125.83% | 164.10% |
Average Days of Receivables |
15.73 | 171.49 | 48.32 | 48.75 | 39.67 | 80.58 | 89.85 | 95.36 | 171.23 | 60.16 |
Research and Development Expense of Revenue |
2,806.42% | 1,672.54% | 2,767.22% | 2,932.72% | 1,585.00% | 1,138.70% | 1,324.85% | 1,363.24% | 2,657.28% | 7,921.98% |
Selling, General and Administrative Expense of Revenue |
1,637.00% | 1,302.04% | 7,772.29% | 13,005.43% | 55,706.09% | 2,535.32% | 5,261.31% | 5,626.58% | 7,781.36% | 13,565.38% |
Intangible Assets out of Total Assets |
0.13 | 0.05 | 0.06 | 0.05 | 0.03 | 0.15 | 0.50 | 0.68 | 0.51 | 0.61 |
Share Based Compensation of Revenue |
924.55% | 701.40% | 5,338.13% | 10,528.30% | 50,236.96% | 898.31% | 1,275.77% | 2,161.62% | 4,445.43% | 6,969.23% |
Graham Net Nets |
(1.10) | 13.32 | 24.21 | 29.52 | 79.95 | (4.58) | (2,362.27) | (26.81) | (5.46) | (4.78) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 932.01 | 203,856.21 | 459,643.82 | 424,836.70 | 397,818.40 |
Earnings Yield |
(2,694.92%) | (1,622.38%) | (2,937.11%) | (3,757.35%) | (17,754.23%) | (2,069.55%) | (216,849.45%) | (3,018.52%) | (792.79%) | (1,034.31%) |
Free Cash Flow Yield |
(2,276.49%) | (1,726.00%) | (2,143.69%) | (1,494.43%) | (1,317.40%) | (367.82%) | (115,905.00%) | (1,422.53%) | (267.32%) | (381.73%) |
Revenue per Share |
0.80 | 1.03 | 0.69 | 0.66 | 0.77 | 3.91 | 433.33 | 1,110.00 | 810.00 | 364.00 |
Operating CF per Share |
(23.99) | (21.20) | (30.49) | (32.69) | (56.06) | (99.71) | (23,062.33) | (51,046.00) | (38,538.00) | (50,027.00) |
Capex per Share |
(0.26) | (0.27) | (0.81) | (2.43) | (0.52) | 0.00 | (118.67) | (129.00) | (36.00) | (1,888.00) |
Free Cash Flow per Share |
(24.25) | (21.47) | (31.30) | (35.12) | (56.58) | (99.71) | (23,181.00) | (51,175.00) | (38,574.00) | (51,915.00) |
Cash per Share |
6.57 | 27.65 | 52.47 | 81.53 | 353.98 | 155.56 | 5.67 | 1,175.00 | 4,517.00 | 318.00 |
Shareholders Equity per Share |
0.79 | 21.98 | 47.44 | 87.52 | 363.59 | (67.59) | (42,587.33) | (86,410.00) | (68,366.00) | (50,003.00) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
Book value per Share |
0.79 | 21.98 | 47.44 | 87.52 | 363.59 | (67.59) | (42,587.33) | (86,410.00) | (68,366.00) | (50,003.00) |
Free Cash Flow |
(10.91) | (8.34) | (6.60) | (6.35) | (3.36) | (1.96) | (6.95) | (5.12) | (3.86) | (5.19) |
Working Capital |
(0.59) | 7.40 | 8.78 | 14.69 | 21.10 | 2.14 | (13.65) | (9.07) | (7.83) | (5.77) |
Capital Expenditures |
(0.12) | (0.11) | (0.17) | (0.44) | (0.03) | — | (0.04) | (0.01) | 0.00 | (0.19) |
Net Current Asset Value |
(0.59) | 7.40 | 8.78 | 14.53 | 20.61 | (2.49) | (14.17) | (9.65) | (8.08) | (6.51) |
EV/EBIT |
0.14 | 0.86 | 0.69 | 0.74 | 0.78 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.32 | 0.26 | 1.17 | 3.67 | 0.67 | 0.00 | 0.27 | 0.12 | 0.04 | 5.19 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.59 | 0.52 | 0.47 | 0.46 | 32.17 | 63.90 | 56.85 | 14.44 | 2.68 | 1.57 |
Cash ROIC |
(329.50%) | (43.28%) | (31.33%) | (20.77%) | (7.85%) | (32.72%) | 56.76% | 63.97% | 62.31% | 111.15% |
Accounts Receivable Turnover |
3.53 | 3.86 | 8.26 | 11.41 | 4.18 | 3.14 | 4.26 | 3.31 | 3.68 | 0.73 |
Accounts Payable Turnover |
0.03 | 0.08 | 0.00 | 2.53 | 2.42 | 0.00 | 0.00 | 0.00 | 0.11 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | — | 0.00 | 0.00 | — | — | — | 0.00 | 0.00 |
Average Days of Payables |
20,573.42 | 6,275.14 | 0.00 | 222.22 | 90.36 | 0.00 | 0.00 | 0.00 | 3,455.61 | 8,336,600.00 |
Days of Inventory on Hand |
0.00 | 0.00 | — | 0.00 | 0.00 | — | — | — | 0.00 | 0.00 |
Average Receivables |
0.10 | 0.10 | 0.02 | 0.01 | 0.01 | 0.02 | 0.03 | 0.03 | 0.02 | 0.05 |
Average Payables |
0.91 | 0.34 | 0.18 | 0.11 | 0.08 | 1.04 | 1.92 | 2.17 | 2.37 | 2.42 |
Average Assets |
8.18 | 12.45 | 14.52 | 19.44 | 13.40 | 2.91 | 1.33 | 1.48 | 1.67 | 1.80 |
Average Common Equity |
4.43 | 9.25 | 12.90 | 18.70 | 10.13 | (7.05) | (10.71) | (7.74) | (5.92) | (4.45) |
Columns are period end dates